Deuterated colchicine liposomes based on oligomeric hyaluronic acid modification enhance anti-tumor effect and reduce systemic toxicity.

[1]  Vivek P. Chavda,et al.  Phytochemical-loaded liposomes for anticancer therapy: an updated review. , 2022, Nanomedicine.

[2]  M. Qiu,et al.  A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours , 2020, Cancer Chemotherapy and Pharmacology.

[3]  D. Muntean,et al.  Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin , 2019, Journal of liposome research.

[4]  Xiaoyan Chen,et al.  Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide , 2016, Drug design, development and therapy.

[5]  L. Cai,et al.  NF-κB Affects Proliferation and Invasiveness of Breast Cancer Cells by Regulating CD44 Expression , 2014, PloS one.

[6]  Fei Li,et al.  Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting , 2014, Pharmaceutical Research.

[7]  T. Gant.  Using deuterium in drug discovery: leaving the label in the drug. , 2014, Journal of medicinal chemistry.

[8]  F. Gao,et al.  The use of HA oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan glycocalyx for breast cancer therapy. , 2013, Biomaterials.

[9]  M. Shchepinov,et al.  Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids , 2013, Redox biology.

[10]  Feng Gao,et al.  The High and Low Molecular Weight Forms of Hyaluronan Have Distinct Effects on CD44 Clustering , 2012, The Journal of Biological Chemistry.

[11]  F. Ahmad,et al.  Role of CD44 in tumour progression and strategies for targeting , 2012, Journal of drug targeting.

[12]  M. Manjili,et al.  CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. , 2012, Human pathology.

[13]  M. Zöller,et al.  CD44v6 Coordinates Tumor Matrix-triggered Motility and Apoptosis Resistance* , 2011, The Journal of Biological Chemistry.

[14]  D. Marina,et al.  Anti-VEGF Therapy in Breast and Lung Mouse Models of Cancers , 2010, Journal of Biomedicine and Biotechnology.

[15]  Xiao-Xuan Ye,et al.  HER2 and VEGF expression in breast cancer and their correlations , 2010 .

[16]  D. Harman.  Origin and evolution of the free radical theory of aging: a brief personal history, 1954–2009 , 2009, Biogerontology.

[17]  F. Szoka,et al.  Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. , 2008, Molecular pharmaceutics.

[18]  S. Nilsson,et al.  The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. , 2005, Experimental cell research.

[19]  B. Bhattacharyya,et al.  The B‐ring substituent at C‐7 of colchicine and the α‐C‐terminus of tubulin communicate through the “tail–body” interaction , 2004, Proteins.

[20]  Gopal Chakrabarti,et al.  Thermodynamics of Colchicinoid-Tubulin Interactions , 1996, The Journal of Biological Chemistry.

[21]  Brygida Berse,et al.  Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.

[22]  B. Bhattacharyya,et al.  Role of B-ring of colchicine in its binding to tubulin. , 1981, Indian journal of biochemistry & biophysics.

[23]  E. Niel,et al.  Colchicine today. , 2006, Joint, bone, spine : revue du rhumatisme.